Introduction to Anti-Human GAD2/GAD65 Antibody (SAA2744)
Anti-Human GAD2/GAD65 Antibody (SAA2744) is a highly specific and sensitive antibody that targets the glutamic acid decarboxylase (GAD) enzymes, specifically GAD2 and GAD65. GAD enzymes are responsible for the conversion of glutamate to gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. Dysfunction of GAD enzymes has been linked to various neurological disorders, making Anti-Human GAD2/GAD65 Antibody a valuable tool in research and diagnostic applications.
Structure of Anti-Human GAD2/GAD65 Antibody (SAA2744)
Anti-Human GAD2/GAD65 Antibody (SAA2744) is a monoclonal antibody produced by hybridoma technology. It is composed of two identical heavy chains and two identical light chains, with a total molecular weight of approximately 150 kDa. The antibody has an immunoglobulin G (IgG) isotype, which allows it to efficiently bind to its target antigens with high specificity and affinity.
Activity of Anti-Human GAD2/GAD65 Antibody (SAA2744)
Anti-Human GAD2/GAD65 Antibody (SAA2744) has been extensively validated for its activity in various applications, including western blotting, immunohistochemistry, and immunofluorescence. It has been shown to specifically recognize and bind to GAD2 and GAD65 proteins in human tissue samples, with minimal cross-reactivity to other antigens. This high specificity allows for accurate detection and quantification of GAD enzymes in various biological samples.
Application of Anti-Human GAD2/GAD65 Antibody (SAA2744)
1. Research on neurological disorders
The role of GAD enzymes in neurological disorders, such as epilepsy, Parkinson’s disease, and schizophrenia, has been extensively studied. Anti-Human GAD2/GAD65 Antibody (SAA2744) can be used in research to investigate the expression and activity of GAD enzymes in these disorders. It can also be used to study the effects of potential therapeutic interventions on GAD enzymes.
2. Diagnostic tool for neurological disorders
The specific binding of Anti-Human GAD2/GAD65 Antibody (SAA2744) to GAD enzymes makes it a valuable diagnostic tool for neurological disorders. It can be used in immunohistochemistry to detect the presence and distribution of GAD enzymes in tissue samples, providing valuable information for the diagnosis and treatment of these disorders.
3. Biomarker for type 1 diabetes
GAD65 is a major autoantigen in type 1 diabetes, and the presence of autoantibodies against GAD65 has been used as a biomarker for the early detection of this disease. Anti-Human GAD2/GAD65 Antibody (SAA2744) can be used in research to study the role of GAD65 autoantibodies in the development and progression of type 1 diabetes.
4. Development of GAD enzyme inhibitors
GAD enzymes have been identified as potential therapeutic targets for the treatment of neurological disorders. Anti-Human GAD2/GAD65 Antibody (SAA2744) can be used in research to screen and identify potential inhibitors of GAD enzymes. This can aid in the development of novel treatments for these disorders.
5. Study of GABAergic signaling
GABAergic signaling plays a crucial role in regulating neuronal excitability and maintaining the balance between excitation and inhibition in the brain. Anti-Human GAD2/GAD65 Antibody (SAA2744) can be used in research to study the expression and activity of GAD enzymes, providing insights into the regulation of GABAergic signaling in the central nervous system.
Conclusion
Anti-Human GAD2/GAD65 Antibody (SAA2744) is a highly specific and sensitive antibody that targets GAD enzymes, specifically GAD2 and GAD65. Its structure, activity, and application have been extensively
There are no reviews yet.